Atara Biotherapeutics (ATRA) Receivables (2020 - 2025)

Atara Biotherapeutics has reported Receivables for 6 years, with the latest figure at $1.3 million in Q4 2025.

• For the quarter ending Q4 2025, Receivables fell 15.45% year-over-year to $1.3 million; the trailing twelve-month figure through Dec 2025 stood at $1.3 million (down 15.45% YoY), and the FY2025 full-year result was $1.3 million, down 15.45% from the prior year.
• Receivables for Q4 2025 stood at $1.3 million, down from $1.9 million in the prior quarter.
• The five-year high for Receivables was $40.2 million in Q4 2022, with the low at $163000.0 in Q3 2023.
• Historically, Receivables has averaged $8.3 million across 5 years, with a median of $1.3 million in 2024.
• The largest YoY upside for Receivables was 8926.2% in 2024 against a maximum downside of 95.65% in 2024.
• Atara Biotherapeutics' Receivables stood at $986000.0 in 2021, then jumped by 3979.21% to $40.2 million in 2022, then dropped by 15.2% to $34.1 million in 2023, then sank by 95.65% to $1.5 million in 2024, then fell by 15.45% to $1.3 million in 2025.
• The last three Receivables figures came in at $1.3 million (Q4 2025), $1.9 million (Q3 2025), and $8.9 million (Q1 2025), per Business Quant data.